Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A virus hemagglutinin protein H3N2 (HA (H3N2))
- Target
- HA (H3N2)
- Molecular classification
- Viral fusion protein, Viral surface glycoprotein, Class I fusion protein, Receptor-binding protein
01
Overview
Hemagglutinin is a homotrimeric glycoprotein located on the surface of the influenza A virus. Each monomer of the HA trimer consists of a globular head domain that binds to sialic acid receptors on host cells and a stem (or stalk) domain that facilitates fusion of the viral envelope with the host cell membrane after endocytosis. The H3N2 subtype of hemagglutinin has been responsible for widespread seasonal influenza outbreaks in humans since 1968. HA is essential for viral entry and is the principal target of neutralizing antibodies elicited by natural infection or vaccination. Its antigenic sites overlap with the receptor-binding site, making it prone to antigenic drift—a major driver of immune escape and the need for continuous vaccine updates[1][2][3][4][6][7].
- Other names
- Hemagglutinin H3N2HA H3N2Influenza virus H3N2 HAH3N2 HA protein
02
Mechanism of action
Neutralizing antibodies block receptor binding or membrane fusion steps Entry inhibitors prevent conformational changes required for fusion
03
Biological functions
Viral attachment to host cellMediating membrane fusion between virus and host cellEvasion of host immune responseDetermining host specificity and cell tropism
04
Disease associations
Infection (influenza)Pandemic and seasonal influenza transmission
05
Safety considerations
Antigenic drift leading to vaccine escapePotential for highly pathogenic variants if cleavage site mutatesHypervariability of the head domain can reduce vaccine/antibody efficacy
06
Interacting drugs
Influenza vaccines (targeting HA)
2 more in the full profile.
07
Biomarkers
HA subtype (H3N2) mutations for vaccine strain selectionAntibody titers to HA for immune status monitoring
Beyond the preview
Go deeper on Influenza A virus hemagglutinin protein H3N2 (HA (H3N2)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A virus hemagglutinin protein H3N2 (HA (H3N2)).